[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BioTechTraderSD Truth HunterTruth Hunter posts on X about $rlyb, $tnya, $140share, breakout the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence stocks XXXXX% finance XXXXX%
Social topic influence $rlyb #1, $tnya #21, $140share #1, breakout 10.53%, shell 5.26%, staff 5.26%, $biib 5.26%, at least 5.26%, balance sheet 5.26%, banger XXXX%
Top assets mentioned Biogen Inc (BIIB) Amgen, Inc. (AMGN) ADC Therapeutics SA (ADCT)
Top posts by engagements in the last XX hours
"$TNYA double positive PR"
X Link 2025-12-11T21:02Z XXX followers, XXX engagements
"Would not be surprised to see $RLYB get bought out in tandem with their C5 data this month. Given they are essentially a shell have laid off XX% of their staff and the $BIIB C5 deal in October it makes sense to give their legacy VCs an exit (many with averages $10)"
X Link 2025-12-09T16:29Z XXX followers, XXX engagements
"I'll at least give $TNYA credit for doing offering immediately instead of creating baggies chasing the news"
X Link 2025-12-11T21:03Z XXX followers, XXX engagements
"$RLYB unstoppable. Breakout"
X Link 2025-12-10T14:49Z XXX followers, XXX engagements
"Oh boy every chatroom gonna be chasing $RLYB soon"
X Link 2025-12-10T16:21Z XXX followers, XXX engagements
"With $1.40/share cash on balance sheet $RLYB has good chance to XXX% + on this month's C5 readout. If program validated they will be moving into two phase X trials in 2026"
X Link 2025-12-11T17:03Z XXX followers, XXX engagements
"$RLYB - Whatever is coming this month is going to be a banger for shareholders. Explains why no funds are selling"
X Link 2025-12-11T18:29Z XXX followers, XXX engagements
"$RLYB has FIVE very underwater VCs. They want an exit and I have seen deals done with them before in situations like this. Whatever is coming will create significant value"
X Link 2025-12-11T19:09Z XXX followers, XXX engagements
"$TNYA followed by offering LOL"
X Link 2025-12-11T21:02Z XXX followers, XXX engagements
"$RLYB - interesting theory. CEO of $RLYB is former head of research at Alexion (now part of AstraZeneca). Alexion specialized in C5 inhibitors and has one recently approved (ravulizumab). 1/2"
X Link 2025-12-11T22:55Z XXX followers, XXX engagements
"Continue to add to $rlyb ahead of topline cohort 1+2 c5 inhibition data. XX% below cash with two c5a inhibitors in pipeline. Two trials to begin 2026. Think we see major pop on heels of $ifrx $amgn"
X Link 2025-11-11T15:46Z XXX followers, XXX engagements
"$RLYB nearing major breakout area. Topline C5 knockdown + safety from Cohort X + X in the next few weeks. XX% below cash in a very hot space"
X Link 2025-11-11T18:59Z XXX followers, XXX engagements
"$JSPR $ADCT $CLNN $BDTX all down on data. Biotech top may finally be in"
X Link 2025-12-03T16:17Z XXX followers, XXX engagements
"Sleeper $RLYB one of last December data plays with minimal risk. Trades XX% below cash with potentially best in class C5 inhibitor. Two phase X programs to potentially start 2026. Very mispriced here ahead of topline PK/PD data"
X Link 2025-12-03T16:25Z XXX followers, XXX engagements
"Looks like $ELDN has positive topline data coming"
X Link 2025-10-17T11:01Z XXX followers, XXX engagements
"$rlyb breakout coming ahead of December data which will determine future of the company. $1.40/share in cash"
X Link 2025-12-09T14:59Z XXX followers, XXX engagements
"$RLYB non stop uptrend. Buyout on C5 data IMO"
X Link 2025-12-10T14:50Z XXX followers, XXX engagements
"So AstraZeneca has two FDA approved C5 inhibitors thanks to Alexion and is investing in multiple more programs. Makes sense that they absorb $RLYB given their huge investment in C5 programs and infrastructure. We will see"
X Link 2025-12-11T22:55Z XXX followers, XXX engagements